Aktaviron - instructions for use, dose, side effects, contraindications

Excipients: microcrystalline cellulose - 40 mg, milk sugar (lactose monohydrate) - 40 mg, povidone KZO - 7 mg; talc - 1.5 mg; magnesium stearate - 1.5 mg; film sheath opedrai II red (polyvinyl alcohol 2 mg, titanium dioxide 0.5175 mg, iron oxide black 0.015 mg, talc 0.74 mg, 1.184 iron oxide red 0.4075 mg, iron oxide yellow 0.31 mg , macrogol 4000 - 1.01 mg) -5 mg.

One 125 mg tablet contains active substance: Tilorone hydrochloride - 125 mg;

Excipients: microcrystalline cellulose - 54 mg; sugar milk (lactose monohydrate) - 54 mg; povidone KZO - 12 mg; talc - 2.5 mg; magnesium stearate - 2.5 mg; film sheath: opedrai II red (polyvinyl alcohol - 3.2 mg, titanium dioxide - 0.828 mg, iron oxide black - 0.024 mg, talc - 1.184 mg, iron oxide red - 0.652, iron oxide yellow - 0.496 mg, macroline 4000 - 1.616 mg) - 8 mg.

Description:Tablets covered with a film coat from reddish-brown to brown, round biconvex forms. Two layers are visible on the cross-section. The core of the tablet is orange with impregnations of a lighter and darker color.

Pharmacotherapeutic group:Antiviral immunostimulating agent - inducer of interferon formation

ATX: & nbsp

L.03.A.X Other immunostimulants

Pharmacodynamics:

A low molecular weight synthetic interferon inducer that stimulates the formation of alpha, beta and gamma interferons in the body. The main producers of interferon in response to the introduction of Tyloron are intestinal epithelial cells, hepatocytes, T-lymphocytes, neutrophils and granulocytes.After taking the drug inside, the maximum production of interferon is determined in the sequence of the intestine - liver - blood after 4-24 hours.

In human leukocytes induces the synthesis of interferon. Stimulates bone marrow stem cells, depending on the dose, enhances antibody formation, reduces the degree of immunosuppression, restores the ratio of T-suppressors and T-helpers. The mechanism of antiviral action is associated with the inhibition of the translation of virus-specific proteins in infected cells, as a result of which the reproduction of viruses is suppressed. Effective against pathogens of viral hepatitis, herpesviruses (including cytomegalovirus).

Pharmacokinetics:

Suction. After taking the drug inside tilorone quickly absorbed from the digestive tract. Bioavailability is about 60%.

Distribution. About 80% of the drug binds to plasma proteins.

Metabolism and excretion. The drug is not biotransformed and does not accumulate in the body. It is excreted almost unchanged through the intestine (about 70%) and urine (about 9%). The half-life of the drug (T 1/2) is 48 h.

Indications:

In adults:

Prevention and treatment of influenza and ARVI;
For the treatment of viral hepatitis A, B and C;
For the treatment of herpetic infection;
For the treatment of cytomegalovirus infection;
As a part of complex therapy of allergic and viral encephalomyelitis (including multiple sclerosis, leukoencephalitis, uveoencephalitis);
As part of a comprehensive therapy of urogenital and respiratory chlamydia;
As part of a comprehensive therapy for pulmonary tuberculosis.

In children older than 7 years the drug is used:

For treatment of influenza and ARVI.

Contraindications:

Hypersensitivity to the components of the drug;
Pregnancy;
The period of breastfeeding (lactation);
Children's age (up to 7 years);
Lactose intolerance, lactase deficiency, glucose-galactose malabsorption.

Pregnancy and lactation:

During pregnancy, during breastfeeding, and also for children under the age of 7, the use of the drug is contraindicated. The use of the drug in patients with diabetes mellitus by appointment of a doctor.

Dosing and Administration:

Inside, after eating. Adults use the drug in a dosage of 125 mg:

For the treatment of influenza and acute respiratory viral infection, the drug is prescribed 125-250 mg per day, 1-2 days, then 125 mg per day after 48 hours. The course dose is 0.75 g (6 tablets).
For the prevention of influenza and SARS - 125 mg once a week for 4-6 weeks. The course dose is 0.75 g (6 tablets).
For the treatment of viral hepatitis A, the dose of the drug on the first day is 125 mg twice a day, then go on to receive 125 mg per day after 48 hours. The course dose is 1.25 mg (10 tablets).
When treating acute hepatitis B in the initial phase of treatment on the first and second day, the dose of 125 mg twice a day, then 125 mg per day after 48 hours. The course dose is 2 g (16 tablets).
In case of protracted hepatitis B in the first day, the dose of 125 mg twice a day, then 125 mg per day after 48 hours. The course dose is 2.5 g (20 tablets).
In chronic hepatitis B in the initial phase of treatment, the total dose is 2.5 g (20 tablets). In the first 2 days, the daily dose of 250 mg, then go to receive 125 mg per day after 48 hours. In the continuation phase of treatment, the total dose is from 1.25 g (10 tablets) to 2.5 g (20 tablets), with the drug prescribe a dose of 125 mg per week. The course dose of the drug varies from 3.75 g to 5 g, the duration of treatment is 3.5-6 months.
In acute hepatitis C on the first and second day of treatment, the drug is prescribed at a dose of 125 mg per day, then 125 mg per day after 48 hours. The course dose is 2.5 g (20 tablets).
In chronic hepatitis C in the initial phase of treatment, the total dose is 2.5 g (20 tablets). In the first 2 days, the daily dose of 250 mg, then go to receive 125 mg per day after 48 hours.In the continuation of treatment, the total dose is 2.5 g (20 tablets), with the drug administered at a dose of 125 mg per week. The course dose is 5 g (40 tablets), the duration of treatment is 6 months.
In the complex treatment of neuroviral infections - 125-250 mg per day in the first two days of treatment, then 125 mg per day after 48 hours. The dose is set individually, the duration of treatment is 3-4 weeks. Multiple sclerosis - 125 mg per day after 48 hours (only 10 tablets).
To treat herpetic, cytomegalovirus infection, the dose of the drug in the first 2 days is 125 mg, then take 125 mg per day after 48 hours. The course dose is -1.25 - 2.5 g (10-20 tablets).
With urogenital and respiratory chlamydia, the drug is given at a dose of 125 mg per day for the first 2 days, then 125 mg / day after 48 hours. The course dose is 1.25 g (10 tablets).
With the complex therapy of pulmonary tuberculosis in the first 2 days, the drug is prescribed 250 mg per day, then 125 mg per day after 48 hours. The course dose is 2.5 g (20 tablets).

Children over 7 years of age use the drug in a dosage of 60 mg.

In uncomplicated forms of influenza and other acute respiratory viral infections, the drug is prescribed in a dose of 60 mg (1 tablet) once a day after meals on the first 2 days of treatment and on the 4th day of treatment (48 hours after taking the second pill). The course dose is 0.18 g (3 tablets).
When complications of influenza and other acute respiratory infections develop, the drug is taken 60 mg once a day for the first 2 days of treatment, then 60 mg at 48 hours on the 4th and 6th days. The course dose is 0.24 g (4 tablets).

Side effects:

Possible side effects when used. Allergic reactions. Dyspeptic phenomena, short-term chills. In case of development of the listed adverse reactions urgently consult a doctor. If any of the side effects listed in the manual are aggravated, or if you notice any other side effects not listed in the instructions, tell your doctor.

Overdose:

To date, cases of drug overdose are unknown.

Interaction:

Compatible with antibiotics, drugs for the treatment of viral and bacterial diseases.

Special instructions:

Precautions for use. 1 tablet of the drug in a dosage of 60 mg contains: 40 mg lactose monohydrate (about 0.004 bread units (XE)). 1 tablet of the drug in a dosage of 125 mg contains: 54 mg lactose monohydrate (about 0.0054 bread units (XE)). The use of the drug in patients with diabetes mellitus by appointment of a doctor. In the complex treatment of neuroviral infections, the drug is used under the supervision of a doctor.

Effect on the ability to drive transp. cf. and fur:

Data on the effect of the drug on the ability to drive vehicles, mechanisms when used in the recommended doses are not.

Form release / dosage:

Film-coated tablets are 60 mg and 125 mg.

Packaging:

6 or 10 tablets per contour cell package. For 1, 2, 3, 5 or 10 contour mesh packages, together with the instructions for use, are placed in a pack of cardboard. Packing for hospitals: 500 tablets per can of polymer. By 1, 2, 3, 4 banks with instructions for use are placed in boxes of corrugated cardboard.

Storage conditions:

In a dry, the dark place at a temperature of no higher than 25 ° C. Keep out of the reach of children.

Leave conditions. The drug in a dosage of 60 mg (for children from 7 years old) is released by prescription. The drug in a dosage of 125 mg is dispensed without a prescription.

Shelf life:

3 years. Do not use after the expiration date.

Terms of leave from pharmacies:On prescription

Registration number:LP-001394

Date of registration:28.12.2011 / 01.11.2012

Expiration Date:Unlimited

The owner of the registration certificate:ZIO-HEALTH, JSC ZIO-HEALTH, JSC Russia

Manufacturer: & nbsp

ZIO-HEALTH, JSC Russia

Information update date: & nbsp04.07.2017

Illustrated instructions

Instructions

Aktaviron (Aktaviron)